Reported 15 days ago
Core Scientific's board has called on shareholders to vote in favor of its proposed $9 billion sale to CoreWeave, highlighting potential benefits such as cost savings and synergies. The all-stock deal, valued at $20.40 per share, faces opposition from Two Seas Capital, the largest shareholder, who argues it undervalues the company and poses economic risks. Despite the dissent, the board believes this acquisition is the best path for its stockholders.
Source: YAHOO